FOXO4-DRI

FOXO4-D-Retro-Inverso Senolytic Peptide

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

A synthetic peptide designed to disrupt a specific protein interaction that allows senescent cells to evade programmed cell death. Studied in the emerging field of senolytics — approaches aimed at selectively clearing aged, dysfunctional cells from tissues to improve tissue function.

Plain English

Researchers study FOXO4-DRI because it was designed to block a survival mechanism that senescent cells use to remain in tissues beyond their useful lifespan. Senescent cells — sometimes called zombie cells — have stopped dividing but do not die as normal cells do, and they release inflammatory signals that may contribute to aging and age-related disease. Scientists are interested in whether selectively clearing these cells could improve tissue function and slow certain aspects of biological aging. Research is currently limited to animal models, and human clinical translation has not yet been established.

Overview

FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4–p53 protein–protein interaction specifically within senescent cells, releasing p53 from FOXO4 nuclear retention and allowing it to initiate apoptosis. Because this interaction is selectively upregulated in senescent cells, the peptide triggers apoptosis specifically in senescent (not normal) cells. Developed by Peter de Keizer's laboratory at Erasmus University Medical Center (Erasmus MC), Rotterdam, it reversed frailty, fur density loss, and renal function decline in fast-aged progeroid and naturally aged mice at remarkably low doses — establishing the first peptide-based senolytic proof of concept.

Research Summary

FOXO4-DRI has preclinical proof-of-concept data from a 2017 Cell publication in fast-aged progeroid and naturally aged mice, including restoration of selected fitness, fur, and renal-function measures through senescent-cell clearance. The evidence base is limited and has not established human efficacy, safety, pharmacokinetics, or dosing. The D-retro-inverso design may affect protease stability, but human tissue exposure and clearance remain unknown.

Research Areas

  • Cellular senescence clearance
  • Senolytics
  • FOXO4/p53 biology
  • Frailty reversal
  • Longevity

Safety & Risks

Serious Risks

  • No human safety data; human risk profile is unknown
  • Potential elimination of beneficial senescent cells (paracrine tissue repair role)
  • Possible stem cell pool depletion
  • Human pharmacokinetics and tissue accumulation are unknown

Reported Side Effects

  • Unknown in humans
  • Transient reversible alopecia observed in mice (followed by regrowth)
  • Potential off-target apoptosis in non-senescent cells at supratherapeutic doses
United States
Research use only; no demonstrated human efficacy or safety
United Kingdom
Research use only
Australia
Research use only
Canada
Research use only

Citations & Sources